NK Cell Biotech Enkayce Pharma Secures Tens of Millions in Series A++ Funding Led by 3SBio and Top-Tier State-Owned Investors, Files for IPO

Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article only provides an introduction to drugs related to healthcare, not a recommendation of treatment plans (if involved); it does not constitute any investment advice.

On November 22, 2024, at 8:00 AM, Enka Therapeutics (Shanghai Enka Cell Technology Co., Ltd.) announced the completionTens of Millions of Yuan in A++ Round Financing, this round of financing was led by3SBio Leads Investment, Zhangke Herun, Yijin Capitaland other follow-up investors. The funds raised in this round will be used to accelerate the research and development and clinical trial progress of Enkaiphar's pipeline products.

Enkaisai Medicine byTian Zhigang, Academician of the Chinese Academy of Engineering and the European Academy of SciencesLed by its core technology team, the company focuses on the research and development and production of innovative cell drug technologies based on NK cells, aiming to provide patients with more effective and safer precision immunotherapy solutions. In March 2020, supported by the Shanghai municipal government, Zhangjiang Administrative Committee, and Zhangjiang Group, EnCay Therapeutics settled in the Zhangjiang Cell Industrial Park. In 2024, two NK cell products from EnCay Therapeutics have successively received clinical trial (IND) approvals from the U.S. FDA and China's CDE. EnCay Therapeutics has successfully transitioned from laboratory research to industrialization and made a leap from preclinical to clinical stages. The company will initiate Phase I clinical trials for the aforementioned products by the end of this year. Meanwhile, in non-oncology fields, multiple IIT projects are currently underway.

Dr. Fang Fang, CEO of Enkaicell, stated: “NK cells are the ‘natural killers’ of tumors, viruses, and aging cells, which will greatly make up for the shortcomings of CAR-T cell therapy. Synthetic NK cells (SnyNK™) have the potential to break through the drug target limitations of CAR, achieving precision, multifunctionality, intelligence, and controllability, and are expected to advance into autoimmune diseases and age-related degenerative diseases. Moreover, NK cell products inherently possess the conditions for ‘universal’ and ‘off-the-shelf’ supply, allowing for batch production from a manufacturing perspective, reducing production costs, and making the price more affordable. The future development prospects in the field of cell therapy are very promising. We are very grateful to our new and old shareholders who support us despite the capital winter, and we are confident in advancing our NK cell products to the next stage.”

With the support of this A++ round of financing, Enkaiphar will continue to innovate, enrich its product pipeline, develop core technologies, and advance the clinical research of cellular products.

Source:Enkaisai Pharmaceutical Official Website

According to Qichacha,Enkai SaiyaoRaised nearly 200 million RMB through four rounds of financing over four years since its establishment.

Source: Qichacha

-END-